Anova launches AI-powered patient matching platform to speed clinical trial enrollment
Clinical trial enrollment has long been a bottleneck in drug development
Clinical trial enrollment has long been a bottleneck in drug development
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The product will be marketed by Dr. Reddy's Laboratories Inc.
Subscribe To Our Newsletter & Stay Updated